New Roche Award for Antibody-based Cancer Therapy Research

          New Roche Award for Antibody-based Cancer Therapy Research

  PR Newswire

  PENZBERG, Germany, May 15, 2013

PENZBERG, Germany, May 15, 2013 /PRNewswire/ --

Researchers from academia throughout Europe are invited to participate

In a newly created award, pRED`s Discovery Oncology unit of Roche (SIX: RO,
ROG; OTCQX: RHHBY) in Penzberg, Germany invites European researchers to submit
abstracts which describe their scientific work in the field of tumor-selective
membrane targets for antibody-based cancer therapy. The award aims to honor
and support outstanding research in the academia field and will further
strengthen Roche´s interaction with the international research community.

"Roche has a long tradition of successful exchange with many research
institutions all over the world," states Klaus Bosslet, Head of Discovery
Oncology Penzberg. "With the new award we emphasize our commitment to
intensifying collaboration with academia and continuing support of innovative
cancer research."

The abstracts will be reviewed by a jury consisting of scientific experts from
academia and Roche. Qualified applicants include graduate students and
postdoctoral fellows from the research labs based in Europe. The authors of
the ten best contributions will be invited to the Roche Penzberg campus near
Munich, for oral presentation, poster discussion and award ceremony in
November 2013. The three winners will be selected at the symposium and receive
an award of 4,000 €, 2,000 €, and 1,000 €, respectively.

For submission and related information, please visit . The deadline for abstract submission is August
15, 2013.

About Roche pRED

Roche's Pharma Research and Early Development organization - Roche pRED -
consists of some 2,500 scientists and clinicians with a shared vision of
excellence in science, a proud heritage of healthcare innovation and a
commitment to deliver new and effective medicines to patients. Working in
partnership with Roche's world-leading Diagnostics Division, Roche pRED
strives to make personalized healthcare a reality, and change the practice of
medicine for future generations. Roche pRED focuses on four therapeutic areas:
oncology, neuroscience, virology and cardiovascular-metabolism at six
strategic sites worldwide. For more information:

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused
healthcare with combined strengths in pharmaceuticals and diagnostics. Roche
is the world's largest biotech company, with truly differentiated medicines in
oncology, infectious diseases, inflammation, metabolism and neuroscience.
Roche is also the world leader in in vitro diagnostics and tissue-based cancer
diagnostics, and a frontrunner in diabetes management. Roche's personalised
healthcare strategy aims at providing medicines and diagnostic tools that
enable tangible improvements in the health, quality of life and survival of
patients. In 2012 Roche had over 82,000 employees worldwide and invested over
8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss
francs. Genentech, in the United States, is a wholly owned member of the Roche
Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For
more information, please visit .

All trademarks used or mentioned in this release are protected by law.

For further information please contact: Roche Diagnostics GmbH Dr. Burkhard
Ziebolz Communication Penzberg Phone: +49-8856-60-4830 Email: Roche Diagnostics GmbH Dr. Johannes Ritter Head of
Communication Penzberg Phone: +49-8856-60-4223 Email:
Press spacebar to pause and continue. Press esc to stop.